EA029678B9 - Четвертичные соли пиперидиния - Google Patents

Четвертичные соли пиперидиния

Info

Publication number
EA029678B9
EA029678B9 EA201500209A EA201500209A EA029678B9 EA 029678 B9 EA029678 B9 EA 029678B9 EA 201500209 A EA201500209 A EA 201500209A EA 201500209 A EA201500209 A EA 201500209A EA 029678 B9 EA029678 B9 EA 029678B9
Authority
EA
Eurasian Patent Office
Prior art keywords
piperidinium
quaternary salts
oabs
copd
acetoxy
Prior art date
Application number
EA201500209A
Other languages
English (en)
Other versions
EA029678B1 (ru
EA201500209A1 (ru
Inventor
Кэтлин Э. Клэренс-Смит
Томас Н. Чейс
Original Assignee
Чейс Фамасьютикалз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чейс Фамасьютикалз Корпорейшн filed Critical Чейс Фамасьютикалз Корпорейшн
Publication of EA201500209A1 publication Critical patent/EA201500209A1/ru
Publication of EA029678B1 publication Critical patent/EA029678B1/ru
Publication of EA029678B9 publication Critical patent/EA029678B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к фармацевтическим композициям, содержащим галид 1-алкил-1-метил-4-[(2,2-дифенил-2-пропокси)ацетокси]пиперидиния, описываемый формулой I, в качестве активного ингредиента, и их применению для лечения синдрома гиперактивного мочевого пузыря (OABS), хронических обструктивных заболеваний легких (COPD) или астмы.
EA201500209A 2012-08-09 2013-07-30 Четвертичные соли пиперидиния EA029678B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681415P 2012-08-09 2012-08-09
PCT/US2013/052626 WO2014025569A1 (en) 2012-08-09 2013-07-30 Piperidinium quaternary salts

Publications (3)

Publication Number Publication Date
EA201500209A1 EA201500209A1 (ru) 2015-05-29
EA029678B1 EA029678B1 (ru) 2018-04-30
EA029678B9 true EA029678B9 (ru) 2018-07-31

Family

ID=50068488

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500209A EA029678B9 (ru) 2012-08-09 2013-07-30 Четвертичные соли пиперидиния

Country Status (14)

Country Link
US (1) US9896416B2 (ru)
EP (1) EP2882711B1 (ru)
JP (1) JP6345665B2 (ru)
KR (2) KR102240999B1 (ru)
CN (2) CN104603108A (ru)
AU (1) AU2013300009B2 (ru)
BR (1) BR112015002832B1 (ru)
CA (1) CA2881182C (ru)
EA (1) EA029678B9 (ru)
HK (1) HK1211572A1 (ru)
IL (1) IL236996A0 (ru)
IN (1) IN2015DN01018A (ru)
MX (1) MX356386B (ru)
WO (1) WO2014025569A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265128A4 (en) 2015-03-06 2018-09-12 Chase Pharmaceuticals Corporation Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
EP4354912A3 (en) 2019-08-22 2024-04-24 Ofinno, LLC Policy control for multiple accesses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (ru) 1973-07-12 1974-06-20
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
DE10129832A1 (de) * 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
SI1713473T1 (sl) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
US8548786B2 (en) * 2005-08-12 2013-10-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neuronal avalanche assay
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
SE0600876L (sv) 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
WO2007123465A1 (en) 2006-04-24 2007-11-01 Astrazeneca Ab New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder
JP2012530050A (ja) * 2010-03-15 2012-11-29 ラマクリシュナ、ラメシャ アンダガル 塩酸プロピベリンの合成
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
EA038489B1 (ru) * 2012-09-05 2021-09-06 Чейс Фамасьютикалз Корпорейшн Антихолинэргическая нейропротективная композиция и способы

Also Published As

Publication number Publication date
WO2014025569A1 (en) 2014-02-13
US20150203452A1 (en) 2015-07-23
HK1211572A1 (en) 2016-05-27
IN2015DN01018A (ru) 2015-06-26
CN104603108A (zh) 2015-05-06
EP2882711B1 (en) 2017-10-25
BR112015002832A2 (ru) 2017-07-04
US9896416B2 (en) 2018-02-20
CA2881182A1 (en) 2014-02-13
KR20150040355A (ko) 2015-04-14
JP6345665B2 (ja) 2018-06-20
AU2013300009A1 (en) 2015-02-26
EP2882711A4 (en) 2016-02-10
MX2015001769A (es) 2015-05-08
EA029678B1 (ru) 2018-04-30
EP2882711A1 (en) 2015-06-17
BR112015002832B1 (pt) 2022-08-16
CN108658842A (zh) 2018-10-16
KR102240999B1 (ko) 2021-04-15
EA201500209A1 (ru) 2015-05-29
KR20200022522A (ko) 2020-03-03
IL236996A0 (en) 2015-03-31
JP2015524469A (ja) 2015-08-24
MX356386B (es) 2018-05-28
CA2881182C (en) 2021-01-26
AU2013300009B2 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
PH12016501439A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
IN2014DN09434A (ru)
MX2016002794A (es) Compuestos antiproliferativos.
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201791780A1 (ru) Ингаляционный раствор тиотропия для небулайзерного распыления
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
MX350793B (es) Pirroldicarboxamidas condensadas y su uso como agentes farmaceuticos.
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA029678B9 (ru) Четвертичные соли пиперидиния
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2013175347A3 (en) Compositions and methods for treatment of respiratory disorders
NZ724063A (en) Pyrazine derivatives having pharmaceutical activity
IN2013DE00880A (ru)
IN2013MU01152A (ru)

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent